Testing effectiveness (Phase 2)UnknownNCT02398552
What this trial is testing
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
Who this might be right for
Metastatic Renal Cell Carcinoma
Peking University Cancer Hospital & Institute 80